Loading…

4CPS-245 Prevention of refeeding syndrome in patients on parenteral nutrition: a review of appropriateness

Background and ImportanceRefeeding syndrome (RFS) is a metabolic disorder that can be triggered after nutritional replacement. This condition can be life-threatening, so early identification and prevention is important.Aim and ObjectivesDescribe a system of screening and nutritional support in patie...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2023-03, Vol.30 (Suppl 1), p.A208-A208
Main Authors: Iglesias Rodrigo, M, Sebastián Carrasco, C, Sangrador Pelluz, C, Meca Casasnovas, N, Salazar González, F, Tenas Rius, B, Nicolás Picó, J
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page A208
container_issue Suppl 1
container_start_page A208
container_title European journal of hospital pharmacy. Science and practice
container_volume 30
creator Iglesias Rodrigo, M
Sebastián Carrasco, C
Sangrador Pelluz, C
Meca Casasnovas, N
Salazar González, F
Tenas Rius, B
Nicolás Picó, J
description Background and ImportanceRefeeding syndrome (RFS) is a metabolic disorder that can be triggered after nutritional replacement. This condition can be life-threatening, so early identification and prevention is important.Aim and ObjectivesDescribe a system of screening and nutritional support in patients at risk of RFS. Assess the degree of adequacy of initial parenteral nutrition (TPN) to published NICE guidelines.Material and MethodsRetrospective observational study including patients from January 2020 to September 2022 identified with RFS risk, according to NICE guidelines criteria, at the beginning of TPN.Variables collected were: age, sex, weight, height, service, low/no intake in 5–10 days prior to starting TPN, type of RFS risk (high or extreme), kilocalories (Kcal) of TPN at baseline and at reaching total requirements, time to establishment of total kcal on TPN and development of RFS (decrease in serum levels of potassium, phosphate, magnesium in the first 72 hours).Results33 patients were included. The mean age was 59,6 years (SD: 15,5). 54,5% were men. The mean BMI was 20,2 (SD: 4,0). 33,3% were surgery patients; 27,3% onco-haematology; 24,2% digestive; 9.1% critical care; 6,1% others. 75,8% of the patients had low/no intake prior to the introduction of TPN. A total of 90,9% were at high risk of developing RFS. The mean kcal/kg of TPN at the start was 20,4 (SD: 3,7). In 63,6% of patients total kcals were instituted within 2 days, and in 36,4% within 3 days. 3 patients developed RFS, all at high risk, 2 of them being onco-haematological.Conclusion and RelevanceMost patients who developed RFS were onco-haematologic, a group at risk for RFS, and had little/no intake prior to the initiation of TPN.In line with the recommendations established by NICE guidelines, the kcal/kg provided by TPN at baseline are higher than recommended (20.4 vs 10 kcal/kg). In addition, the total kcal were reached between 2–3 days, the recommendations being between 4–7 days. Only 9.1% of the patients developed RFS, so that future studies could consider a less restrictive caloric start in TPN than that proposed in the aforementioned guidelines.The role of the pharmacist, together with the rest of the multidisciplinary team, has allowed early detection and prevention of developing RFS in 90.9% of the patients.References and/or AcknowledgementsConflict of InterestNo conflict of interest.
doi_str_mv 10.1136/ejhpharm-2023-eahp.429
format article
fullrecord <record><control><sourceid>proquest_bmj_j</sourceid><recordid>TN_cdi_proquest_journals_2808526994</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2808526994</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1199-764483ed3b9e192cd53c819717c3ee87c7234162c7e65004895cf437a8bb73753</originalsourceid><addsrcrecordid>eNpFkMtKAzEUhoMoWGpfQQKup-Y6SdxJUSsULKjrkJk5Y1PazJhMK-7c-KI-iTPUy-r8i__C-RA6p2RKKc8vYb1qVy5uM0YYz8Ct2qlg5giNGBEqMyYXx39a5qdokpIviORcG8HNCG3EbPmYMSG_Pj6XEfYQOt8E3NQ4Qg1Q-fCC03uoYrMF7ANuXed7T8LNoGMvIboNDrsu-iF5hV2f3Ht4Gzpc28amjd51ECClM3RSu02Cyc8do-fbm6fZPFs83N3PrhdZQakxmcqF0BwqXhighpWV5KWmRlFVcgCtSsW4oDkrFeSSEKGNLGvBldNFobiSfIwuDr39-usOUmfXzS6GftIyTbRkuem_HyN2cBXb9b-BEjuAtb9g7QDWDmBtD5Z_A5kkcE0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2808526994</pqid></control><display><type>article</type><title>4CPS-245 Prevention of refeeding syndrome in patients on parenteral nutrition: a review of appropriateness</title><source>PubMed Central (Open Access)</source><creator>Iglesias Rodrigo, M ; Sebastián Carrasco, C ; Sangrador Pelluz, C ; Meca Casasnovas, N ; Salazar González, F ; Tenas Rius, B ; Nicolás Picó, J</creator><creatorcontrib>Iglesias Rodrigo, M ; Sebastián Carrasco, C ; Sangrador Pelluz, C ; Meca Casasnovas, N ; Salazar González, F ; Tenas Rius, B ; Nicolás Picó, J</creatorcontrib><description>Background and ImportanceRefeeding syndrome (RFS) is a metabolic disorder that can be triggered after nutritional replacement. This condition can be life-threatening, so early identification and prevention is important.Aim and ObjectivesDescribe a system of screening and nutritional support in patients at risk of RFS. Assess the degree of adequacy of initial parenteral nutrition (TPN) to published NICE guidelines.Material and MethodsRetrospective observational study including patients from January 2020 to September 2022 identified with RFS risk, according to NICE guidelines criteria, at the beginning of TPN.Variables collected were: age, sex, weight, height, service, low/no intake in 5–10 days prior to starting TPN, type of RFS risk (high or extreme), kilocalories (Kcal) of TPN at baseline and at reaching total requirements, time to establishment of total kcal on TPN and development of RFS (decrease in serum levels of potassium, phosphate, magnesium in the first 72 hours).Results33 patients were included. The mean age was 59,6 years (SD: 15,5). 54,5% were men. The mean BMI was 20,2 (SD: 4,0). 33,3% were surgery patients; 27,3% onco-haematology; 24,2% digestive; 9.1% critical care; 6,1% others. 75,8% of the patients had low/no intake prior to the introduction of TPN. A total of 90,9% were at high risk of developing RFS. The mean kcal/kg of TPN at the start was 20,4 (SD: 3,7). In 63,6% of patients total kcals were instituted within 2 days, and in 36,4% within 3 days. 3 patients developed RFS, all at high risk, 2 of them being onco-haematological.Conclusion and RelevanceMost patients who developed RFS were onco-haematologic, a group at risk for RFS, and had little/no intake prior to the initiation of TPN.In line with the recommendations established by NICE guidelines, the kcal/kg provided by TPN at baseline are higher than recommended (20.4 vs 10 kcal/kg). In addition, the total kcal were reached between 2–3 days, the recommendations being between 4–7 days. Only 9.1% of the patients developed RFS, so that future studies could consider a less restrictive caloric start in TPN than that proposed in the aforementioned guidelines.The role of the pharmacist, together with the rest of the multidisciplinary team, has allowed early detection and prevention of developing RFS in 90.9% of the patients.References and/or AcknowledgementsConflict of InterestNo conflict of interest.</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2023-eahp.429</identifier><language>eng</language><publisher>London: British Medical Journal Publishing Group</publisher><subject>Conflicts of interest ; Late breaking abstracts ; Nutrition ; Parenteral nutrition</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2023-03, Vol.30 (Suppl 1), p.A208-A208</ispartof><rights>European Association of Hospital Pharmacists 2023. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2023 European Association of Hospital Pharmacists 2023. No commercial re-use. See rights and permissions. Published by BMJ.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Iglesias Rodrigo, M</creatorcontrib><creatorcontrib>Sebastián Carrasco, C</creatorcontrib><creatorcontrib>Sangrador Pelluz, C</creatorcontrib><creatorcontrib>Meca Casasnovas, N</creatorcontrib><creatorcontrib>Salazar González, F</creatorcontrib><creatorcontrib>Tenas Rius, B</creatorcontrib><creatorcontrib>Nicolás Picó, J</creatorcontrib><title>4CPS-245 Prevention of refeeding syndrome in patients on parenteral nutrition: a review of appropriateness</title><title>European journal of hospital pharmacy. Science and practice</title><addtitle>Eur J Hosp Pharm</addtitle><description>Background and ImportanceRefeeding syndrome (RFS) is a metabolic disorder that can be triggered after nutritional replacement. This condition can be life-threatening, so early identification and prevention is important.Aim and ObjectivesDescribe a system of screening and nutritional support in patients at risk of RFS. Assess the degree of adequacy of initial parenteral nutrition (TPN) to published NICE guidelines.Material and MethodsRetrospective observational study including patients from January 2020 to September 2022 identified with RFS risk, according to NICE guidelines criteria, at the beginning of TPN.Variables collected were: age, sex, weight, height, service, low/no intake in 5–10 days prior to starting TPN, type of RFS risk (high or extreme), kilocalories (Kcal) of TPN at baseline and at reaching total requirements, time to establishment of total kcal on TPN and development of RFS (decrease in serum levels of potassium, phosphate, magnesium in the first 72 hours).Results33 patients were included. The mean age was 59,6 years (SD: 15,5). 54,5% were men. The mean BMI was 20,2 (SD: 4,0). 33,3% were surgery patients; 27,3% onco-haematology; 24,2% digestive; 9.1% critical care; 6,1% others. 75,8% of the patients had low/no intake prior to the introduction of TPN. A total of 90,9% were at high risk of developing RFS. The mean kcal/kg of TPN at the start was 20,4 (SD: 3,7). In 63,6% of patients total kcals were instituted within 2 days, and in 36,4% within 3 days. 3 patients developed RFS, all at high risk, 2 of them being onco-haematological.Conclusion and RelevanceMost patients who developed RFS were onco-haematologic, a group at risk for RFS, and had little/no intake prior to the initiation of TPN.In line with the recommendations established by NICE guidelines, the kcal/kg provided by TPN at baseline are higher than recommended (20.4 vs 10 kcal/kg). In addition, the total kcal were reached between 2–3 days, the recommendations being between 4–7 days. Only 9.1% of the patients developed RFS, so that future studies could consider a less restrictive caloric start in TPN than that proposed in the aforementioned guidelines.The role of the pharmacist, together with the rest of the multidisciplinary team, has allowed early detection and prevention of developing RFS in 90.9% of the patients.References and/or AcknowledgementsConflict of InterestNo conflict of interest.</description><subject>Conflicts of interest</subject><subject>Late breaking abstracts</subject><subject>Nutrition</subject><subject>Parenteral nutrition</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpFkMtKAzEUhoMoWGpfQQKup-Y6SdxJUSsULKjrkJk5Y1PazJhMK-7c-KI-iTPUy-r8i__C-RA6p2RKKc8vYb1qVy5uM0YYz8Ct2qlg5giNGBEqMyYXx39a5qdokpIviORcG8HNCG3EbPmYMSG_Pj6XEfYQOt8E3NQ4Qg1Q-fCC03uoYrMF7ANuXed7T8LNoGMvIboNDrsu-iF5hV2f3Ht4Gzpc28amjd51ECClM3RSu02Cyc8do-fbm6fZPFs83N3PrhdZQakxmcqF0BwqXhighpWV5KWmRlFVcgCtSsW4oDkrFeSSEKGNLGvBldNFobiSfIwuDr39-usOUmfXzS6GftIyTbRkuem_HyN2cBXb9b-BEjuAtb9g7QDWDmBtD5Z_A5kkcE0</recordid><startdate>202303</startdate><enddate>202303</enddate><creator>Iglesias Rodrigo, M</creator><creator>Sebastián Carrasco, C</creator><creator>Sangrador Pelluz, C</creator><creator>Meca Casasnovas, N</creator><creator>Salazar González, F</creator><creator>Tenas Rius, B</creator><creator>Nicolás Picó, J</creator><general>British Medical Journal Publishing Group</general><general>BMJ Publishing Group LTD</general><scope>K9.</scope></search><sort><creationdate>202303</creationdate><title>4CPS-245 Prevention of refeeding syndrome in patients on parenteral nutrition: a review of appropriateness</title><author>Iglesias Rodrigo, M ; Sebastián Carrasco, C ; Sangrador Pelluz, C ; Meca Casasnovas, N ; Salazar González, F ; Tenas Rius, B ; Nicolás Picó, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1199-764483ed3b9e192cd53c819717c3ee87c7234162c7e65004895cf437a8bb73753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Conflicts of interest</topic><topic>Late breaking abstracts</topic><topic>Nutrition</topic><topic>Parenteral nutrition</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Iglesias Rodrigo, M</creatorcontrib><creatorcontrib>Sebastián Carrasco, C</creatorcontrib><creatorcontrib>Sangrador Pelluz, C</creatorcontrib><creatorcontrib>Meca Casasnovas, N</creatorcontrib><creatorcontrib>Salazar González, F</creatorcontrib><creatorcontrib>Tenas Rius, B</creatorcontrib><creatorcontrib>Nicolás Picó, J</creatorcontrib><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Iglesias Rodrigo, M</au><au>Sebastián Carrasco, C</au><au>Sangrador Pelluz, C</au><au>Meca Casasnovas, N</au><au>Salazar González, F</au><au>Tenas Rius, B</au><au>Nicolás Picó, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>4CPS-245 Prevention of refeeding syndrome in patients on parenteral nutrition: a review of appropriateness</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><stitle>Eur J Hosp Pharm</stitle><date>2023-03</date><risdate>2023</risdate><volume>30</volume><issue>Suppl 1</issue><spage>A208</spage><epage>A208</epage><pages>A208-A208</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>Background and ImportanceRefeeding syndrome (RFS) is a metabolic disorder that can be triggered after nutritional replacement. This condition can be life-threatening, so early identification and prevention is important.Aim and ObjectivesDescribe a system of screening and nutritional support in patients at risk of RFS. Assess the degree of adequacy of initial parenteral nutrition (TPN) to published NICE guidelines.Material and MethodsRetrospective observational study including patients from January 2020 to September 2022 identified with RFS risk, according to NICE guidelines criteria, at the beginning of TPN.Variables collected were: age, sex, weight, height, service, low/no intake in 5–10 days prior to starting TPN, type of RFS risk (high or extreme), kilocalories (Kcal) of TPN at baseline and at reaching total requirements, time to establishment of total kcal on TPN and development of RFS (decrease in serum levels of potassium, phosphate, magnesium in the first 72 hours).Results33 patients were included. The mean age was 59,6 years (SD: 15,5). 54,5% were men. The mean BMI was 20,2 (SD: 4,0). 33,3% were surgery patients; 27,3% onco-haematology; 24,2% digestive; 9.1% critical care; 6,1% others. 75,8% of the patients had low/no intake prior to the introduction of TPN. A total of 90,9% were at high risk of developing RFS. The mean kcal/kg of TPN at the start was 20,4 (SD: 3,7). In 63,6% of patients total kcals were instituted within 2 days, and in 36,4% within 3 days. 3 patients developed RFS, all at high risk, 2 of them being onco-haematological.Conclusion and RelevanceMost patients who developed RFS were onco-haematologic, a group at risk for RFS, and had little/no intake prior to the initiation of TPN.In line with the recommendations established by NICE guidelines, the kcal/kg provided by TPN at baseline are higher than recommended (20.4 vs 10 kcal/kg). In addition, the total kcal were reached between 2–3 days, the recommendations being between 4–7 days. Only 9.1% of the patients developed RFS, so that future studies could consider a less restrictive caloric start in TPN than that proposed in the aforementioned guidelines.The role of the pharmacist, together with the rest of the multidisciplinary team, has allowed early detection and prevention of developing RFS in 90.9% of the patients.References and/or AcknowledgementsConflict of InterestNo conflict of interest.</abstract><cop>London</cop><pub>British Medical Journal Publishing Group</pub><doi>10.1136/ejhpharm-2023-eahp.429</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2047-9956
ispartof European journal of hospital pharmacy. Science and practice, 2023-03, Vol.30 (Suppl 1), p.A208-A208
issn 2047-9956
2047-9964
language eng
recordid cdi_proquest_journals_2808526994
source PubMed Central (Open Access)
subjects Conflicts of interest
Late breaking abstracts
Nutrition
Parenteral nutrition
title 4CPS-245 Prevention of refeeding syndrome in patients on parenteral nutrition: a review of appropriateness
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T03%3A05%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_j&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=4CPS-245%E2%80%85Prevention%20of%20refeeding%20syndrome%20in%20patients%20on%20parenteral%20nutrition:%20a%20review%20of%20appropriateness&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Iglesias%20Rodrigo,%20M&rft.date=2023-03&rft.volume=30&rft.issue=Suppl%201&rft.spage=A208&rft.epage=A208&rft.pages=A208-A208&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2023-eahp.429&rft_dat=%3Cproquest_bmj_j%3E2808526994%3C/proquest_bmj_j%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b1199-764483ed3b9e192cd53c819717c3ee87c7234162c7e65004895cf437a8bb73753%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2808526994&rft_id=info:pmid/&rfr_iscdi=true